TriGUARD 3 Data Does Not Pass Muster: FDA Experts

The panel of experts said the clinical trial data is insufficient for Keystone Heart’s TriGUARD 3, and the little data there is shows use of the cerebral embolic protection device increases risk for stroke and 30-day mortality.